Clinical Trial Update: Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating ensartinib with carboplatin, pemetrexed, and bevacizumab for ALK-positive non-small cell lung cancer at Stage IIIC/IV or recurrent dise…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• CARBOPLATIN (Carboplatin)
• Ensartinib (Ensartinib)
• Pemetrexed (pemetrexed)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING